|
Summary
December 2005, Vol. 5, No. 12, Pages 1571-1584
, DOI 10.1517/14712598.5.12.1571
Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseasesJakob Reiser1LSU Health Sciences Center, Gene Therapy Program, New Orleans, LA, USA 2Tulane University Health Sciences Center, Department of Pediatrics, New Orleans, Louisiana 70112, USA 3Tulane University Health Sciences Center, Department of Pharmacology, New Orleans, Louisiana 70112, USA 4Tulane University Health Sciences Center, Cancer Center, New Orleans, Louisiana 70112, USA 5Tulane National Primate Research Center, Gene Therapy Program, Tulane University, New Orleans, LA, USA The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs. Forward Links to Citing ArticlesTran Cong Toai, Huynh Duy Thao, Nguyen Phuong Thao, Ciro Gargiulo, Phan Kim Ngoc, Pham Hung Van, D. Michael Strong. (2009) In vitro culture and differentiation of osteoblasts from human umbilical cord blood. Cell and Tissue Banking Online publication date: 30-Jul-2009. CrossRef Mi-Hyeon You, Wang-Joon Kim, Wooyoung Shim, Sang-Rim Lee, Gwang Lee, Sangdun Choi, Dae-Yong Kim, Yong Man Kim, Hyunsoo Kim, Sang-Uk Han. (2009) Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. Journal of Gastroenterology and Hepatology Online publication date: 1-Jul-2009. CrossRef Jessamine P. Winer, Paul A. Janmey, Margaret E. McCormick, Makoto Funaki. (2009) Bone Marrow-Derived Human Mesenchymal Stem Cells Become Quiescent on Soft Substrates but Remain Responsive to Chemical or Mechanical Stimuli. Tissue Engineering Part A 15:1, 147-154 Online publication date: 1-Feb-2009. CrossRef Vanessa Fritz, Danièle Noël, Céline Bouquet, Paule Opolon, Romain Voide, Florence Apparailly, Pascale Louis-Plence, Carine Bouffi, Hicham Drissi, Chao Xie, Michel Perricaudet, Ralph Müller, Edward Schwarz, Christian Jorgensen. (2008) Antitumoral Activity and Osteogenic Potential of Mesenchymal Stem Cells Expressing the Urokinase-Type Plasminogen Antagonist Amino-Terminal Fragment in a Murine Model of Osteolytic Tumor. Stem Cells 26:11, 2981-2990 Online publication date: 1-Dec-2008. CrossRef Claudia Piccoli, Rosella Scrima, Maria Ripoli, Mauro Di Ianni, Beatrice Del Papa, Annamaria D'Aprile, Giovanni Quarato, Maria Paola Martelli, Giuseppe Servillo, Claudio Ligas, Domenico Boffoli, Antonio Tabilio, Nazzareno Capitanio. (2008) Transformation by Retroviral Vectors of Bone Marrow-Derived Mesenchymal Cells Induces Mitochondria-Dependent cAMP-Sensitive Reactive Oxygen Species Production. Stem Cells 26:11, 2843-2854 Online publication date: 1-Dec-2008. CrossRef Lucia Kucerova, Miroslava Matuskova, Andrea Pastorakova, Silvia Tyciakova, Jana Jakubikova, Roman Bohovic, Veronika Altanerova, Cestmir Altaner. (2008) Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. The Journal of Gene Medicine 10:10, 1071-1082 Online publication date: 1-Nov-2008. CrossRef Felix IL Clanchy, Richard O Williams. (2008) Plasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease. Expert Opinion on Biological Therapy 8:10, 1507-1519 Online publication date: 1-Oct-2008. Summary | Full Text | PDF (313 KB) | PDF Plus (328 KB) David M. Ricks, Robert Kutner, Xian-Yang Zhang, David A. Welsh, Jakob Reiser. (2008) Optimized Lentiviral Transduction of Mouse Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells and Development 17:3, 441-450 Online publication date: 1-Jul-2008. CrossRef Gemma E. Rooney, Cathal Moran, Siobhan S. McMahon, Thomas Ritter, Martin Maenz, Alexander Flügel, Peter Dockery, Timothy O'Brien, Linda Howard, Anthony J. Windebank, Frank P. Barry. (2008) Gene-Modified Mesenchymal Stem Cells Express Functionally Active Nerve Growth Factor on an Engineered Poly Lactic Glycolic Acid (PLGA) Substrate. Tissue Engineering Part A 14:5, 681-690 Online publication date: 1-Jun-2008. CrossRef J C Roth, D T Curiel, L Pereboeva. (2008) Cell vehicle targeting strategies. Gene Therapy 15:10, 716-729 Online publication date: 1-Jun-2008. CrossRef S Kumar, D Chanda, S Ponnazhagan. (2008) Therapeutic potential of genetically modified mesenchymal stem cells. Gene Therapy 15:10, 711-715 Online publication date: 1-Jun-2008. CrossRef T D Strong, M A Gebska, H C Champion, A L Burnett, T J Bivalacqua. (2008) Stem and endothelial progenitor cells in erection biology. International Journal of Impotence Research 20:3, 243-254 Online publication date: 1-Jun-2008. CrossRef J Xu, J Qu, L Cao, Y Sai, C Chen, L He, L Yu. (2008) Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. The Journal of Pathology 214:4, 472-481 Online publication date: 1-Apr-2008. CrossRef Young-Sin Jeong, Eun Joong Kim, Chang-Koo Shim, Joon Hyuk Hou, Jung Mogg Kim, Han-Gon Choi, Won-Ki Kim, Yu-Kyoung Oh. (2008) Modulation of biodistribution and expression of plasmid DNA following mesenchymal progenitor cell-based delivery. Journal of Drug Targeting 16:5, 405-414 Online publication date: 1-Jan-2008. Summary | Full Text | PDF (499 KB) | PDF Plus (552 KB) Y Gheisari, M Soleimani, K Azadmanesh, S Zeinali, Y Gheisari, M Soleimani, K Azadmanesh, S Zeinali. (2008) Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods. Cytotherapy 10:8, 815-823 Online publication date: 1-Jan-2008. Summary | Full Text | PDF (544 KB) | PDF Plus (545 KB) |
|





Author for correspondence
TOC Alert